Biomarker for diagnosing central precocious puberty in females and uses thereof

Abstract

This application relates to the technical field of biomarkers, and in particular, to a biomarker for diagnosing central precocious puberty (CPP) in females and uses thereof. This application provides a biomarker for diagnosing CPP in females. The biomarker is one, two, or three of leptin, RBP4, or chemerin. Experiments performed in this application show that female children with CPP exhibit leptin, RBP4, and chemerin levels in peripheral blood significantly higher than those of healthy children, and that serum leptin and RBP4 levels in CPP patients change early during development of CPP, indicating that these three adipokines may participate in the development of CPP.

Dependencies are inferred from the claim text.